Adel Boughlita

Adel Boughlita

Auto-generated profile, based on publicly available information

Adel Boughlita

Institute for Regenerative Medicine and Biotherapy, University of Montpellier, INSERM, CHU Montpellier, Montpellier, France

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2023 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
JNJean NAKHLE
Jean NAKHLE
KKKhattar Khattar
Khattar Khattar
TÖTülin Özkan
Tülin Özkan
ABAdel Boughlita
Adel Boughlita
DMDaouda ABBA MOUSSA
Daouda ABBA MOUSSA
MVMarie-Luce VIGNAIS
Marie-Luce VIGNAIS
Glioblastomas (GBM) are heterogeneous tumors with high metabolic plasticity. Their poor prognosis is linked to the presence of glioblastoma stem cells (GSC), which support resistance to therapy, notably to temozolomide (TMZ). Mesenchymal stem cells (MSC) recruitment to GBM contributes to GSC chemoresistance, by mechanisms still poorly understood. Here, we provide evidence that MSCs transfer mitochondria to GSCs through tunneling nanotubes, which enhances GSCs resistance to TMZ. More precisely, our metabolomics analyses reveal that MSC mitochondria induce GSCs metabolic reprograming, with a nutrient shift from glucose to glutamine, a rewiring of the tricarboxylic acid cycle from glutaminolysis to reductive carboxylation and increase in orotate turnover as well as in pyrimidine and purine synthesis. Metabolomics analysis of GBM patient tissues at relapse after TMZ treatment documents increased concentrations of AMP, CMP, GMP, and UMP nucleotides and thus corroborate our in vitro analyses. Finally, we provide a mechanism whereby mitochondrial transfer from MSCs to GSCs contributes to GBM resistance to TMZ therapy, by demonstrating that inhibition of orotate production by Brequinar (BRQ) restores TMZ sensitivity in GSCs with acquired mitochondria. Altogether, these results identify a mechanism for GBM resistance to TMZ and reveal a metabolic dependency of chemoresistant GBM following the acquisition of exogenous mitochondria, which opens therapeutic perspectives based on synthetic lethality between TMZ and BRQ.Significance: Mitochondria acquired from MSCs enhance the chemoresistance of GBMs. The discovery that they also generate metabolic vulnerability in GSCs paves the way for novel therapeutic approaches.

25 May 2023
Verified
Other
Open access
PDF file
JNJean NAKHLE
Jean NAKHLE
KKKhattar Khattar
Khattar Khattar
TÖTülin Özkan
Tülin Özkan
ABAdel Boughlita
Adel Boughlita
DMDaouda ABBA MOUSSA
Daouda ABBA MOUSSA
MVMarie-Luce VIGNAIS
Marie-Luce VIGNAIS
Effects of MSC mitochondria on GSCs metabolic response to TMZ (A, B) GSC mitochondrial mass and ROS production. FACS analysis of MitoTracker and MitoSox-labeled GSCs after the acquisition of MSC mitochondria and TMZ treatment (24 hr). (A) Mitochondrial mass. (B) ROS production. (A, B) Representative experiments and relative MFI values (mean ± SEM; n=3). One-way ANOVA, *p < 0.05. (C) Expression of Cytochrome c oxidase IV (COX IV). Representative Western blot with the corresponding membrane (MW markers in kDa) as shown in Fig. 3H.

14 June 2023
Verified
Other
Open access
PDF file
JNJean NAKHLE
Jean NAKHLE
KKKhattar Khattar
Khattar Khattar
TÖTülin Özkan
Tülin Özkan
ABAdel Boughlita
Adel Boughlita
DMDaouda ABBA MOUSSA
Daouda ABBA MOUSSA
MVMarie-Luce VIGNAIS
Marie-Luce VIGNAIS
Experimental design and timeline

25 May 2023
Verified
Other
Open access
PDF file
JNJean NAKHLE
Jean NAKHLE
KKKhattar Khattar
Khattar Khattar
TÖTülin Özkan
Tülin Özkan
ABAdel Boughlita
Adel Boughlita
DMDaouda ABBA MOUSSA
Daouda ABBA MOUSSA
MVMarie-Luce VIGNAIS
Marie-Luce VIGNAIS
MSC mitochondria modify the usage of metabolites by GCSs in response to TMZ CTRL Mito TMZ CTRL Mito Mito TMZ (A) Metabolic substrate consumption of GSCs expressed as metabolite initial consumption rates (Biolog MitoPlates). Mean values ± SEM (4 independent experiments). (B) Production of cis-aconitate, succinate and L-malate expressed as a percentage of all TCA metabolites produced in each experimental condition. Tukey boxplots with one-way ANOVA, *p < 0.05, ***p < 0.001.

14 June 2023
Verified
Other
Open access
PDF file
JNJean NAKHLE
Jean NAKHLE
KKKhattar Khattar
Khattar Khattar
TÖTülin Özkan
Tülin Özkan
ABAdel Boughlita
Adel Boughlita
DMDaouda ABBA MOUSSA
Daouda ABBA MOUSSA
MVMarie-Luce VIGNAIS
Marie-Luce VIGNAIS
Metabolite detection in resected GBM from 8 patients, at 1rst resection and at 2nd resection post-TMZ treatment. For each metabolite, the C12/C13 ratios normalized to tissue protein concentrations are indicated.

14 June 2023
Verified
Other
Open access
JNJean NAKHLE
Jean NAKHLE
KKKhattar Khattar
Khattar Khattar
TÖTülin Özkan
Tülin Özkan
ABAdel Boughlita
Adel Boughlita
DMDaouda ABBA MOUSSA
Daouda ABBA MOUSSA
MVMarie-Luce VIGNAIS
Marie-Luce VIGNAIS
Metabolomics analysis of resected GBM from patients, pre- and post-TMZ treatment shows increased nucleotides concentrations. A, Metabolomics analysis were performed on GBM resected tumors from 8 patients, before treatment and after radiotherapy and several cycles (3 to 13) of TMZ treatment. B, MRI profiles and H&E-stained tissue sections of the analyzed GBM tumors, before and after TMZ treatment. Tumor areas at first and second resections are framed. Scale bar, 100 μm. C, Mass spectrometry metabolomics analysis of the resected GBM. The C12/C13 metabolite ratios normalized to tissue protein concentrations are indicated. Out of the 8 patients, 6 followed a similar trend (solid lines), while 2 followed an opposite trend (dotted lines). Statistical analysis by ratio paired Student t test (AMP, GMP, UMP) and Wilcoxon matched-pairs signed-rank test (CMP) on metabolomics data from the 6 patients.